Breaking

News

Filters:
All
Show more filters
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Positive final Phase I results

March 21, 2024
PharmNovo
Neuropathic pain
Clinical trails
Pain management
PN6047

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more →

NIDA funds studies

January 30, 2024
PharmNovo
Neuropathic pain
Clinical trails
Pain management
PN6047

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more →

Meet Olof Breuer, MD, Clinical pharmacology lead

January 30, 2024
Member
Clinical
Clinical study
Lifescience
Neuropathic pain

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more →

A new perspective in pain management and opioid withdrawal relief

January 30, 2024
PharmNovo
OWS
Neuropathic pain
Pain management
PN6047

We are proud to share an article in Dagens Industri about our groundbreaking work with PN6047. Our promising drug candidate not only has the potential to revolutionise pain relief but has also caught the attention of the National Institute on Drug Abuse (NIDA) for its role in opioid withdrawal treatment. Per von Mentzer, our CEO, states: "Our work with PN6047 could open new paths in pain relief. Particularly in neuropathic pain, our research could lead to new insights and novel treatment approaches in various clinical areas." PN6047, a selective DORA, offers a new perspective on both pain management and opioid withdrawal treatment. The results from the Phase I study show promising safety and tolerance, paving the way for further studies on its effects on opioid withdrawal syndrome.

Read more →

Phase IIa studies with WCT

October 18, 2023
Neuropathic pain
Lifescience
Clinical trails
PharmNovo
Paintreatment

Following the successful completion of our phase I study, we are pleased to announce our collaboration with WCT, Worldwide Clinical Trials, as the phase IIa study of our drug candidate PN6047. This partnership underscores our commitment to developing solutions for neuropathic pain. In the upcoming phase IIa study, PharmNovo will investigate the safety, tolerability, pharmacokinetics, and efficacy of their drug candidate PN6047 for individuals affected by neuropathic pain and experiencing Mechanical Allodynia. This distressing symptom, caused by nerve injury, often disrupts daily life and sleep. PN6047 offers a targeted approach to alleviate this condition, aiming to improve the overall pain experience. Insights on its efficacy will aid in designing subsequent phase IIb/III studies.

Read more →

Meet Jesper Kjerulff, Chief operations officer and Global project lead

October 18, 2023
Clinical study
Neuropathic pain
Lifescience
PN6047

In the pharmaceutical development arena, experts like Jesper Kjerulff stand out. As Global project lead and Chief operations officer (COO) of PharmNovo, Jesper Kjerulff is instrumental in propelling the company's groundbreaking project, PN6047, and advancing the field of neuropathic pain management.

Read more →

No results found